The Eden Prairie, Minn.-based company said that the agreement will expand its sales outreach in Asia and open access to one of the larger population centers in the region.
“We continue to expand our presence worldwide and are pleased to extend the reach of our therapy with our Aquadex FlexFlow system into the Indian healthcare centers for patients who are chronically challenged by fluid overload when diuretics have failed. Heart failure is a global issue and there is a worldwide need to provide clinically proven tools to appropriately manage fluid overload. We continue to grow our global presence and look forward to providing further updates as they become available,” chair & CEO John Erb said in a press release.
Last September, CHF Solutions said that it plans to expand into the post-cardiovascular surgery market, specifically with products for patients who need treatment for fluid overload and have failed diuretic therapy.